Monitor says Celgene cancer drug meets late-stage goals
(Reuters) - An independent safety panel determined that Celgene Corp's experimental cancer drug had met the main goal of a late-stage trial by improving progression-free survival in multiple myeloma patients who have relapsed or not responded to prior treatment, the drugmaker said. The study's data safety monitoring board also determined that the pomalidomide drug, given in combination with a low dose of existing treatment dexamethasone, was superior to a high dose of the existing treatment in improving overall survival. ...
Source: news.yahoo.com
No comments:
Post a Comment